The role and mechanism of RNA m6A methylation modification and non-coding RNA in the occurrence of metabolic-related fatty liver disease

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000038060

Enrollment

Unknown

Registered

2020-09-09

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic-related fatty liver disease

Interventions

Gold Standard:Pathologic diagnosis

Index test:Diagnosis&#32

model&#32

of&#32

MAFLD

Eligibility

Sex/Gender

All

Age

16 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with metabolic-related fatty liver disease and apparently normal controls.

Exclusion criteria

Exclusion criteria: Patients with liver cirrhosis and liver cancer.

Design outcomes

Primary

Measure	Time frame
m6A methylation sequencing;Whole transcriptome sequencing;PCR;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactZheng Mengyao

The Second Affiliated Hospital of Kunming Medical University

9196410@qq.com+86 13629658391

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026